Merck's sacituzumab tirumotecan ADC beats Keytruda
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Merck invested in a Chinese‑developed antibody‑drug conjugate, sacituzumab tirumotecan.
- Merck’s Phase 3 lung‑cancer study found the sacituzumab tirumotecan plus Keytruda regimen sharply outperformed Keytruda alone in a subset of patients.
- Merck’s trial result marks a major success for its partnership with the Chinese developer.
Why it matters: Merck and its Chinese partner gain a new market foothold, while patients in the responsive lung‑cancer subgroup receive a more effective regimen, boosting revenue and survival outcomes.
